Transcriptome sequencing and lncRNA-miRNA-mRNA network construction in cardiac fibrosis and heart failure

Wang, Shuo; Lv, Tianjie; Chen, Qincong; Yang, Yan; Xu, Lei; Zhang, Xiaolei; Wang, Enmao; Hu, Xitian; Liu, Yuying

doi:10.1080/21655979.2022.2045839

Cited by 13 publications

(8 citation statements)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…26 Suppression of CCNE2 attenuated the differentiation of myofibroblast after TGF-β1 treatment. 25 The SNP rs2340584 at the CCNE2 locus was reported to be significantly associated with 1-year all-cause death in patients with HFpEF. 27 Cox6b2 encodes a subunit of cytochrome c oxidase (complex IV).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction

Gao,

Chen,

Han

et al. 2024

Circ: Heart Failure

View full text Add to dashboard Cite

BACKGROUND: Heart failure with preserved ejection fraction is a major global public health problem, while effective risk stratification tools are still lacking. We sought to construct a multi-mRNA signature to predict 1-year all-cause death. METHODS: We selected 30 patients with heart failure with preserved ejection fraction who died during 1-year follow-up and 30 who survived in the discovery set. One hundred seventy-one and 120 patients with heart failure with preserved ejection fraction were randomly selected as a test set and a validation set, respectively. We performed mRNA microarrays in all patients. RESULTS: We constructed a 5-mRNA signature for predicting 1-year all-cause death. The scores of the 5-mRNA signature were significantly associated with the 1-year risk of all-cause death in both the test set (hazard ratio, 2.72 [95% CI, 1.98–3.74]; P <0.001) and the validation set (hazard ratio, 3.95 [95% CI, 2.40–6.48]; P <0.001). Compared with a reference model, which included sex, ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) score, history of HF and NT-proBNP (N-terminal pro-B-type natriuretic peptide), the 5-mRNA signature had a better discrimination capability, with an increased area under the curve from 0.696 to 0.813 in the test set and from 0.712 to 0.848 in the validation set. A composite model integrating the 5-mRNA risk score and variables in the reference model demonstrated an excellent discrimination capability, with an area under the curve of 0.861 (95% CI, 0.784–0.939) in the test set and an area under the curve of 0.859 (95% CI, 0.755–0.963) in the validation set. The net reclassification improvement and integrated discrimination improvement indicated that the composite model significantly improved patient classification compared with the reference model in both sets ( P <0.001). CONCLUSIONS: The 5-mRNA signature is a promising predictive tool for 1-year all-cause death and shows improved prognostic power over the established risk scores and NT-proBNP in patients with heart failure with preserved ejection fraction.

show abstract

Section: Discussionmentioning

confidence: 99%

Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction

Gao,

Chen,

Han

et al. 2024

Circ: Heart Failure

View full text Add to dashboard Cite

show abstract

“…MAP3K20-AS1 is a key molecular marker in the transcriptome sequencing of cardiac fibrosis and heart failure. [37] NR2F2-AS1 can affect the proliferation, invasion, and apoptosis of NSCLC cells by regulating miR-320b targeting BMI1 [38] and inducing epithelial-mesenchymal transition in NSCLC by regulating the BVR/ATF-2 pathway through the miR-545-5p/c-Met axis, [39] suggesting that NR2F2-AS1 is a potential therapeutic target for improving NSCLC. AC090948.1 is of great value in predicting the survival of patients with bladder cancer [40] and breast cancer.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have shown that MAP3K20-AS1, NR2F2-AS1, AC090948.1, and AC026355.2 are important in the diagnosis, survival prognosis, and clinical treatment of the disease, whereas CRIM1-DT, AC006213.3, AC008035.1, AL356481.1, AC011477.2, AL031600.2 were identified for the first time in disease prognosis prediction.MAP3K20-AS1 is a key molecular marker in the transcriptome sequencing of cardiac fibrosis and heart failure. [ 37 ] NR2F2-AS1 can affect the proliferation, invasion, and apoptosis of NSCLC cells by regulating miR-320b targeting BMI1 [ 38 ] and inducing epithelial-mesenchymal transition in NSCLC by regulating the BVR/ATF-2 pathway through the miR-545-5p/c-Met axis, [ 39 ] suggesting that NR2F2-AS1 is a potential therapeutic target for improving NSCLC. AC090948.1 is of great value in predicting the survival of patients with bladder cancer [ 40 ] and breast cancer.…”

Section: Discussionmentioning

confidence: 99%

A novel prognostic signature for lung adenocarcinoma based on cuproptosis-related lncRNAs: A Review

Zhao

Zhu

et al. 2022

Medicine

View full text Add to dashboard Cite

Lung adenocarcinoma (LUAD) is a highly heterogeneous disease with complex pathogenesis, high mortality, and poor prognosis. Cuproptosis is a new type of programmed cell death triggered by copper accumulation that may play an important role in cancer. LncRNAs are becoming valuable prognostic factors in cancer patients. The effect of cuproptosis-related lncRNAs (CRlncRNAs) on LUAD has not been clarified. Based on the Cancer Genome Atlas database, CRlncRNAs were screened by co-expression analysis of cuproptosis-related genes and lncRNAs. Using CRlncRNAs, Cox and LASSO regression analyses constructed a risk prognostic model. The predictive efficacy of the model was assessed and validated using survival analysis, receiver operating characteristic curve, univariate and multifactor Cox regression analysis, and principal component analysis. A nomogram was constructed and calibration curves were applied to enhance the predictive efficacy of the model. Tumor Mutational Burden analysis and chemotherapeutic drug sensitivity prediction were performed to assess the clinical feasibility of the risk model. The novel prognostic signature consisted of 5 potentially high-risk CRlncRNAs, MAP3K20-AS1, CRIM1-DT, AC006213.3, AC008035.1, and NR2F2-AS1, and 5 potentially protective CRlncRNAs, AC090948.1, AL356481.1, AC011477.2, AL031600.2, and AC026355.2, which had accurate and robust predictive power for LUAD patients. Collectively, the novel prognostic signature constructed based on CRlncRNAs can effectively assess and predict the prognosis of patients and provide a new perspective for the diagnosis and treatment of LUAD.

show abstract

“…The overexpression of CHRF induces a pathological process and induces apoptosis. The lncRNA CHAER is involved in cardiac remodelling and is expressed during HF in the heart of mice [ 147 ]. The long noncoding RNA PCR2 has shown cardioprotective properties in animal models.…”

Section: Clinical Significance Of Lncrnas In Cardiovascular Diseasesmentioning

confidence: 99%

Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases

Singh

Kim

Choi

et al. 2023

Cells

View full text Add to dashboard Cite

Based on recent research, the non-coding genome is essential for controlling genes and genetic programming during development, as well as for health and cardiovascular diseases (CVDs). The microRNAs (miRNAs), lncRNAs (long ncRNAs), and circRNAs (circular RNAs) with significant regulatory and structural roles make up approximately 99% of the human genome, which does not contain proteins. Non-coding RNAs (ncRNA) have been discovered to be essential novel regulators of cardiovascular risk factors and cellular processes, making them significant prospects for advanced diagnostics and prognosis evaluation. Cases of CVDs are rising due to limitations in the current therapeutic approach; most of the treatment options are based on the coding transcripts that encode proteins. Recently, various investigations have shown the role of nc-RNA in the early diagnosis and treatment of CVDs. Furthermore, the development of novel diagnoses and treatments based on miRNAs, lncRNAs, and circRNAs could be more helpful in the clinical management of patients with CVDs. CVDs are classified into various types of heart diseases, including cardiac hypertrophy (CH), heart failure (HF), rheumatic heart disease (RHD), acute coronary syndrome (ACS), myocardial infarction (MI), atherosclerosis (AS), myocardial fibrosis (MF), arrhythmia (ARR), and pulmonary arterial hypertension (PAH). Here, we discuss the biological and clinical importance of miRNAs, lncRNAs, and circRNAs and their expression profiles and manipulation of non-coding transcripts in CVDs, which will deliver an in-depth knowledge of the role of ncRNAs in CVDs for progressing new clinical diagnosis and treatment.

show abstract

Transcriptome sequencing and lncRNA-miRNA-mRNA network construction in cardiac fibrosis and heart failure

Cited by 13 publications

References 74 publications

Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction

Prognostic Value of a Multi-mRNA Signature for 1-Year All-Cause Death in Hospitalized Patients With Heart Failure With a Preserved Ejection Fraction

A novel prognostic signature for lung adenocarcinoma based on cuproptosis-related lncRNAs: A Review

Clinical Significance of MicroRNAs, Long Non-Coding RNAs, and CircRNAs in Cardiovascular Diseases

Contact Info

Product

Resources

About